| Serplulimab studied in …STUDIED_INderived97 of 97show fewer |
|---|
| → studied in | NCT07177443Phase 3 · recruiting Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma · 97 trials list this drug (69 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07819604Phase 2 · not yet recruiting Serplulimab Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer · 97 trials list this drug (69 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07739758Phase 3 · recruiting A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer · 97 trials list this drug (69 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06860529Phase 2 · recruiting Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer · 97 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07175389Phase 1/Phase 2 · not yet recruiting JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure · 97 trials list this drug (69 active) | — | — | Pancreatic Adenocarcinoma,Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07699939Phase 2 · recruiting Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma · 97 trials list this drug (69 active) | — | — | Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05957510Phase 2 · active not recruiting Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment · 97 trials list this drug (69 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07713745Phase 2 · not yet recruiting Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2) · 97 trials list this drug (69 active) | — | — | Meningioma,Vestibular Schwannoma,Ependymoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07708285Phase 1/Phase 2 · not yet recruiting Luvometinib in Combination With Serplulimab for NF2-Related Tumors · 97 trials list this drug (69 active) | — | — | Meningioma,Vestibular Schwannoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07621484Phase 2 · not yet recruiting HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer · 97 trials list this drug (69 active) | — | — | Malignant Gastric Neoplasm,Gastric Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06128252NA · recruiting Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer · 97 trials list this drug (69 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06497530Phase 2 · recruiting Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC · 97 trials list this drug (69 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07269782Phase 2 · recruiting A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC · 97 trials list this drug (69 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06115642Phase 1 · enrolling by invitation A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors · 97 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05585580Phase 2 · active not recruiting Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy · 97 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07604909Phase 2 · recruiting A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy · 97 trials list this drug (69 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07596121Phase 2 · recruiting Serplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50% · 97 trials list this drug (69 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07113275Phase 3 · recruiting A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer · 97 trials list this drug (69 active) | — | — | Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07283692Phase 2 · recruiting Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT) · 97 trials list this drug (69 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07583511Phase 2 · recruiting Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study · 97 trials list this drug (69 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05765825Phase 2 · active not recruiting Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC · 97 trials list this drug (69 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07231445Phase 1 · recruiting Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer · 97 trials list this drug (69 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07543848Phase 2 · not yet recruiting A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer · 97 trials list this drug (69 active) | — | — | Rectal Neoplasm,Rectal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06280495Phase 2/Phase 3 · recruiting Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients · 97 trials list this drug (69 active) | — | — | Colorectal Neoplasm,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07527520Phase 2 · not yet recruiting Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Multi-center Randomized Control Phase II Trial · 97 trials list this drug (69 active) | — | — | Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07507916Phase 2 · not yet recruiting Dynamic ctDNA-Guided Adjuvant Therapy in cStage III and IVA Gastric or Gastroesophageal Junction Adenocarcinoma · 97 trials list this drug (69 active) | — | — | Gastric Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06850103Phase 2 · recruiting SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases · 97 trials list this drug (69 active) | — | — | Colorectal Neoplasm,Colorectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07466303Phase 2 · not yet recruiting Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer · 97 trials list this drug (69 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07457528Phase 2 · recruiting Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC · 97 trials list this drug (69 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05731726Phase 2 · recruiting Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer · 97 trials list this drug (69 active) | — | — | Rectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06461910Phase 2 · recruiting Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma · 97 trials list this drug (69 active) | — | — | Malignant Gastric Neoplasm,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07446465Phase 4 · not yet recruiting FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer · 97 trials list this drug (69 active) | — | — | Colorectal Neoplasm,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07403435Phase 2 · not yet recruiting Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC · 97 trials list this drug (69 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07381400Phase 2 · not yet recruiting Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study) · 97 trials list this drug (69 active) | — | — | Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05954429Phase 2 · recruiting A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study · 97 trials list this drug (69 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07340489Phase 2 · recruiting Serplulimab for Locally Advanced Cervical Cancer · 97 trials list this drug (69 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05353257Phase 3 · active not recruiting A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer · 97 trials list this drug (69 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07336953Phase 3 · not yet recruiting A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2) · 97 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06727617Phase 2 · recruiting Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors · 97 trials list this drug (69 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07318883Phase 2/Phase 3 · not yet recruiting A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer · 97 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07277842Phase 3 · not yet recruiting PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer · 97 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04063163Phase 3 · completed A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC · 97 trials list this drug (69 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06848699Phase 1/Phase 2 · recruiting A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors · 97 trials list this drug (69 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06368141Phase 2 · recruiting Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer · 97 trials list this drug (69 active) | — | — | Malignant Colon Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06601309Phase 2 · recruiting Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC · 97 trials list this drug (69 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07064876Phase 2 · not yet recruiting Serplulimab Combined With Cryoablation for Early-Stage Non-Small Cell Lung Cancer · 97 trials list this drug (69 active) | — | — | Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07155122Phase 2 · not yet recruiting Efficacy and Safety of Serplulimab Combined With Etoposide and Cisplatin as Neoadjuvant Therapy in Limited-Stage Small-Cell Carcinoma of the Esophageal · 97 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07150949Phase 2 · recruiting Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC) · 97 trials list this drug (69 active) | — | — | Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07134101Phase 2 · not yet recruiting Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01) · 97 trials list this drug (69 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07141771Phase 1/Phase 2 · not yet recruiting An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing · 97 trials list this drug (69 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05787613Phase 2 · active not recruiting A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients · 97 trials list this drug (69 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06781281recruiting NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer. · 97 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06422858Phase 2 · unknown Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma · 97 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06716619Phase 1 · recruiting A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors · 97 trials list this drug (69 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06521866Phase 2 · recruiting Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer · 97 trials list this drug (69 active) | — | — | Colorectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06349980Phase 2 · recruiting A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients. · 97 trials list this drug (69 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06302062Phase 1 · recruiting Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors · 97 trials list this drug (69 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06692491Phase 2 · not yet recruiting Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS · 97 trials list this drug (69 active) | — | — | Rare Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04547166Phase 2/Phase 3 · recruiting A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC) · 97 trials list this drug (69 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05584137Phase 2 · terminated Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC · 97 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05766800Phase 2 · recruiting Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer · 97 trials list this drug (69 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06580665NA · not yet recruiting Cryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung Cancer · 97 trials list this drug (69 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06531291Phase 2 · not yet recruiting Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation · 97 trials list this drug (69 active) | — | — | Malignant Gastric Neoplasm,Malignant Biliary Tract Neoplasm,Pancreatic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06295926Phase 2 · recruiting Serplulimab Combined With CCRT for LS-SCLC. · 97 trials list this drug (69 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05513573Phase 2 · active not recruiting Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC · 97 trials list this drug (69 active) | — | — | Nasopharyngeal Carcinoma by AJCC v8 Stage | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06455072Phase 2 · unknown Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer · 97 trials list this drug (69 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06439550Phase 2 · not yet recruiting Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC · 97 trials list this drug (69 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06433869Phase 2 · recruiting The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites · 97 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06419673Phase 2 · active not recruiting Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer · 97 trials list this drug (69 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05443646Phase 2 · unknown Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients · 97 trials list this drug (69 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06364046NA · unknown Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC · 97 trials list this drug (69 active) | — | — | Carcinoma,Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06354218Phase 2 · recruiting Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age · 97 trials list this drug (69 active) | — | — | Esophageal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06350162Phase 2 · unknown Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC · 97 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06334757Phase 2 · unknown Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure · 97 trials list this drug (69 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05975749Phase 2 · recruiting Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer · 97 trials list this drug (69 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05400265Phase 1 · completed Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor · 97 trials list this drug (69 active) | — | — | Adult Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06195683Phase 2 · unknown Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study. · 97 trials list this drug (69 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04033354Phase 3 · unknown A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC · 97 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04297995Phase 2 · unknown Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors · 97 trials list this drug (69 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05883670unknown Real-world Study of Serplulimab in 2L and Above Treatment of Cervical Cancer · 97 trials list this drug (69 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05769725Phase 2 · unknown A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer · 97 trials list this drug (69 active) | — | — | Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05732493Phase 2 · unknown Short-course Radiotherapy Combined With Chemotherapy and Pd-1 Inhibitor for Locally Advanced Colon Cancer(TORCH-C) · 97 trials list this drug (69 active) | — | — | Malignant Colon Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03941574Phase 2 · unknown A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy · 97 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05501340Phase 1/Phase 2 · unknown PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites · 97 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05442996Phase 1 · unknown A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors · 97 trials list this drug (69 active) | — | — | Adult Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05444374Phase 2 · unknown A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer · 97 trials list this drug (69 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04139135Phase 3 · unknown A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer · 97 trials list this drug (69 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04465734Phase 3 · withdrawn A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC · 97 trials list this drug (69 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04806945Phase 3 · withdrawn A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer · 97 trials list this drug (69 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05354700Phase 2 · unknown A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer · 97 trials list this drug (69 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05239650Phase 2 · not yet recruiting Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC · 97 trials list this drug (69 active) | — | — | Colorectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05290220Phase 2 · unknown HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma · 97 trials list this drug (69 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03973112Phase 2 · unknown A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients · 97 trials list this drug (69 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04947826Phase 2 · unknown Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor Thrombosis · 97 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03468751Phase 1 · unknown Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors · 97 trials list this drug (69 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04301739Phase 3 · not yet recruiting to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC) · 97 trials list this drug (69 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03757936Phase 1 · unknown A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors · 97 trials list this drug (69 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |